High-grade serous ovarian cancer is a detrimental disease. Treatment options in patients with a recurrent disease are dependent on BRCA1/2 mutation status since only patients with known BRCA mutation are eligible for treatment with poly(ADP-ribose) polymerase inhibitors (PARPi). | Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1 2 genes in patients with tubo-ovarian high grade serous carcinoma